Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its ...
Subcutaneous Sarclisa, administered via OBDS, showed non-inferior efficacy to IV Sarclisa in relapsed/refractory multiple ...
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaApproval based on ...
China NMPA approves Sanofi’s Sarclisa in combo with pomalidomide and dexamethasone to treat adult patients with R/R multiple myeloma: Paris Tuesday, January 14, 2025, 10:00 Hrs ...
Sanofi has reported results from its Phase III IRAKLIA trial of Sarclisa (isatuximab) as a potential treatment for multiple ...
French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...
Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved ...
Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its blood cancer drug, Sarclisa (isatuximab) for the treatment of relapsed or ...